PROactive Results - The Diabetes Trial That Could Have Been

Table of Contents

• ABOUT DATAMONITOR HEALTHCARE
  • About the Cardiovascular pharmaceutical analysis team
• EXECUTIVE SUMMARY
  • Introduction
  • Scope and coverage of the Brief
  • Key findings about the the topic
• CHAPTER 1 - BACKGROUND
  • Introduction
    • Epidemiology of diabetes
      • Current prevalence of type 1 and type 2 diabetes
      • Future prevalence of type 2 diabetes
  • Rationale
  • Pharmaceutical agent used
    • Thiazolidinediones
    • Actos
  • Study design
    • Inclusion criteria
    • Exclusion criteria
    • Efficacy evaluations
    • Safety evaluations
    • Baseline characteristics
      • Demography
      • Other patient history.
      • Physical examination and laboratory data.
      • Concomitant medication.
• CHAPTER 2 - RESULTS
  • Study quality
  • Cardiovascular outcomes
  • Metabolic outcomes
  • Changes in medication use
  • Safety
• CHAPTER 3 - CRITICAL EVALUATION
  • Discussion of results
  • Study limitations and comments
  • Conclusion
• APPENDIX
  • Bibliography
    • Epidemiology
    • Clinical trial data
  • Research methodology
  • Disclaimer
• List of Tables
  • Table 1: Prevalence of type 1 and type 2 diabetesacross the seven major markets, 2004
  • Table 2: Future prevalence of type 1 and type 2diabetes in the seven major markets, 2004-12
  • Table 3: Characteristics of patient population atbaseline
  • Table 4: Medications taken by the patient populationat study entry
  • Table 5: Previous macrovascular events
  • Table 6: Cardiovascular outcomes PROactive
  • Table 7: Numbers of first events contributing toprimary endpoints
  • Table 8: Change in laboratory data from baseline
  • Table 9: Change in proportion of patients usingconcomitant medications
  • Table 10: Safety of pioglitazone
• List of Figures
  • Figure 1: Pioglitazones effects on triglyceride andHDL cholesterol levels
  • Figure 2: PROactive study design
  • Figure 3: Inclusion criteria for PROactive
  • Figure 4: PROactive endpoints
  • Figure 5: Overlap of previous macrovascular events
  • Figure 6: Factors possibly contributing to thebeneficial effect of pioglitazone
  • Figure 7: Definition of a serious adverse effect